We use cookies to provide you with a better experience. By continuing to browse the site you are agreeing to our use of cookies in accordance with our Cookie Policy.
  • SKIP TO CONTENT
  • SKIP NAVIGATION
  • Drug Products
    • Books
    • FDAnews Books Library
    • Events
    • Form 483s Database
    • Subscription Newsletters
    • Free Newsletters
    • Webinar Training Pass
    • eCFR and Guidances
  • Device Products
    • Books
    • FDAnews Books Library
    • Events
    • Form 483s Database
    • Subscription Newsletters
    • Free Newsletters
    • Webinar Training Pass
    • eCFR and Guidances
  • Clinical Products
  • Advertising
  • White Papers
  • Contact Us
  • About Us
  • COVID-19
  • Sign In
  • Create Account
  • Sign Out
  • My Account
Home » DOJ Files Charges in $2.1 Billion Telemedicine Health Care Fraud Plot

DOJ Files Charges in $2.1 Billion Telemedicine Health Care Fraud Plot

September 30, 2019

The U.S. Department of Justice has charged 35 defendants involved with telemedicine companies and cancer genetic testing labs for allegedly taking part in a $2.1 billion fraudulent health care scheme.

The defendants made up Medicare billings amounting to more than $2.1 billion for the medically unnecessary genetic tests, the DOJ said, alleging that the scheme traded illegal kickbacks and bribes for Medicare beneficiary referrals.

“Unfortunately, audacious schemes such as those alleged in the indictments are pervasive and exploit the promise of new medical technologies such as genetic testing and telemedicine for financial gain, not patient care,” said Gary L. Cantrell, HHS deputy inspector general for investigations.

View today's stories

Medical Devices Regulatory Affairs

Upcoming Events

  • 15Apr

    Five Telltale Signs You’re Ready for an Electronic TMF System

  • 21Apr

    CDER’s Most Significant Guidance Priorities for 2021: Biosimilars/Biologics, Generics/Exclusivity, Real-World Evidence, Drug Development and Digital Health

  • 26Apr

    MAGI's Clinical Research vConference — Spring 2021

  • 06May

    The World of Post-COVID-19 Clinical Trials: How to Prepare for What’s Coming Next

Featured Products

  • Biological Risk Evaluation and Management for Medical Devices

  • GMP Inspection Preparation Checklist: A Tool for Internal Auditing

Featured Stories

  • FDA logo blue

    Former Indivor Executive Seeks FDA Hearing to Avoid Debarment

  • FDA clears text

    FDA Clears Activ Surgical’s Imaging Module for ActivEdge Platform

  • Bristol Myers Squibb logo

    UK’s NICE Rejects Opdivo and Yervoy Combo for Lung Cancer

  • ClearanceStamp_Orange.gif

    Medtronic Earns De Novo Clearance for AI Colonoscopy System

The Revised ICH E8: A Guide to New Clinical Trial Requirements

Learn More
  • Drug Products
    • Quality
    • Regulatory Affairs
    • GMPs
    • Inspections and Audits
    • Postmarket Safety
    • Submissions and Approvals
    • Research and Development
    • Commercial Operations
  • Device Products
    • Quality
    • Regulatory Affairs
    • QSR
    • Inspections and Audits
    • Postmarket Safety
    • Submissions and Approvals
    • Research and Development
    • Commercial Operations
  • Clinical Products
    • Trial Design
    • Data Integrity
    • GCP
    • Inspections and Audits
    • Transparency
  • Privacy Policy
  • Do Not Sell My Personal Information
Footer Logo

300 N. Washington St., Suite 200, Falls Church, VA 22046, USA

Phone 703.538.7600 – Fax 703.538.7676 – Toll free 888.838.5578

Copyright © 2021. All Rights Reserved. Design, CMS, Hosting & Web Development :: ePublishing